Chemicals and intermediates used in pharmaceutical manufacturing and drug development.
chemXplore tracks 177 projects in pharma, of which 69 are active.
Of the active ones, 37 expansion, 29 new construction and 3 revamp / retrofit.
25 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.
Both dosing regimens reduced systemic disease activity at Week 48; the four-week regimen also improved patient-reported dryness.
The InvestEU-backed financing will support development of its vectorised antibody platform and expansion of its pipeline.
ACR50 response reached 43.7% versus 15.7% with Taltz alone; exploratory results also showed metabolic and patient-reported improvements.
Operating EBITDA rose 14.5% on a constant-currency basis, while the gross margin narrowed as sourcing costs increased.
A second pivotal study found improvement in symptoms by Day 3; the findings will support a planned US regulatory submission.
First GMP batch of plant-derived cholesterol produced at the new Tippecanoe facility; full capacity planned by mid-2027 to support LNP-based therapies.
Oral once-daily 50 mg FXIa inhibitor, given with antiplatelet therapy, cut ischemic stroke risk by 26% versus antiplatelets alone in a 12,327‑patient Phase III trial with similar major bleeding rates.
Phase 1 data show deep, durable PSA reductions at the recommended regimen with no Grade 3+ treatment-related adverse events; combination advancing into Phase 3.
Phase 3 ATTAIN-OSA showed up to 44% AHI reduction, up to 55.9% lower hypoxic burden, ~11–11.5% weight loss, and improvements in blood pressure and inflammation; FDA submission planned by end of 2026.
Data show early LDL‑C lowering with Repatha reduces major cardiovascular events and is cost‑effective for high‑risk patients without prior heart attack or stroke.
active all projects
The 8 with the most active projects, of 27 countries.
